Catalent | CTLT - Les Charges D'Exploitation



Les Charges D'Exploitation Changement Date
Agilent USD 1.44B 27M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Bruker USD 900.9M 124.3M 2025-12
Centene USD 50.96B 30.01B 2025-12
Charles River Laboratories USD 918.41M 2.49B 2025-12
Cigna USD 41.71B 92.12M 2025-12
Danaher USD 5.34B 45.74B 2025-12
Dentsply International USD 423M 1.06B 2025-12
Elevance Health USD 49.17B 5.21B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Humana USD 33.32B 1.07B 2025-12
Illumina USD 903M 69M 2025-12
Intuitive Surgical USD 2B 263.6M 2025-12
IQVIA Holdings USD 1.69B 4.47B 2025-12
J&J USD 17.44B 1.53B 2026-03
Laboratory Of America USD 3.13B 32.4M 2025-12
Lonza CHF 2.9B 184M 2025-06
McKesson USD 104.5B 2.85B 2025-12
Merck EUR 4.78B 669M 2025-12
Merck USD 10.16B 558M 2025-12
Mettler Toledo International USD 777.8M 42.3M 2025-12
Novartis USD 9.8B 61M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Quest Diagnostics USD 2.42B 4.84B 2025-12
Repligen USD 177.94M 1.82M 2025-12
Revvity USD 626.22M 25.62M 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Supernus Pharmaceuticals USD 197.75M 54.54M 2025-12
Thermo Fisher Scientific USD 9.91B 867M 2025-12
UnitedHealth USD 109.96B 1.11B 2025-12
Veradigm USD 188M 61.08M 2022-12
Waters USD 661.85M 1.67B 2025-12
West Pharmaceutical Services USD 642.5M 2.41B 2025-12